Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting
Abstract The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; several prospective studies involving thes...
Main Authors: | Ting Shi, Hong-Hu Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-04-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13045-024-01539-4 |
Similar Items
-
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01) -
Targeted treatment of T-cell acute lymphoblastic leukemia: latest updates from the 2022 ASH Annual Meeting
by: Jieyu Xu, et al.
Published: (2023-03-01) -
Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2023 ASH annual meeting
by: Xubo Gong, et al.
Published: (2024-02-01) -
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01) -
Diagnostics and treatment challenges of Ph-like acute lymphoblastic leukemia: a description of 3 clinical cases
by: K I ZARUBINA, et al.
Published: (2018-07-01)